For the 2022 reporting year, the following ASCO-developed measures are available in the Merit-based Incentive Payment System (MIPS) reporting program. The CMS QPP website lists the complete MIPS Oncology Measures Set. To view the Measures Set, select Oncology/Hematology from the Speciality Measure Set dropdown list.

MIPS Clinical Quality Measures (CQMs)

These measures are available for reporting to CMS in their Merit-based Incentive Payment System (MIPS) Programs. 

Quality ID

(QPP/NQF)

Measure Title

QPP 143

(NQF 0384)

Oncology: Medical and Radiation-Pain Intensity Quantified (CQM)

CMS157v10

(NQF 0384e)

Oncology Medical and Radiation-Pain Intensity Quantified (eCQM)

QPP 144

(NQF 0383)

Oncology: Medical and Radiation-Plan of Care for Pain (CQM)

QPP 450

(NQF 1858)

Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer (CQM)

QPP 451

(NQF 1859)

RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy (CQM)

QPP 452

(NQF 1860)

Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (CQM)

QPP 453

(NQF 0210)

Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better) (CQM)

QPP 455

(NQF 0213)

Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score - better) (CQM)

QPP 457

(NQF 0216)

Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better) (CQM)